Lupin, one of the leading pharmaceutical companies in India, today announced the appointment of Fabrice Egros as President, Asia Pacific and Japan. He will be based in Tokyo, Japan.
Fabrice has over 25 years of experience within the global pharmaceutical industry, having worked in leadership roles encompassing P&L management for new markets, mergers & acquisitions, marketing & commercial, global strategy and business development as well as global clinical development, regulatory and manufacturing.
He will be responsible for Lupin's growth and development across key markets such as Japan, Australia, the Philippines, South East Asia and new markets in the rest of the ASEAN region.
Prior to joining Lupin, Fabrice was with NovaMedica where he was the Deputy CEO/ COO and instrumental in setting up an integrated new pharmaceutical business. Before NovaMedica, he has worked with global majors such as UCB, Sanofi and Parke Davis in various global and regional capacities.
Fabrice holds a Degree in Pharmacy, a MS in clinical pharmacology and a Doctorate in Pharmaceutical Sciences from the University of Paris (School of Medicine and Pharmacy) as well as a MBA from Schiller University. He has also completed Advanced Management Program from Harvard University.
Commenting on the appointment, Nilesh Gupta, managing director, Lupin said, ''We are delighted to have Fabrice join the Lupin family. His deep knowledge of the Asia-Pacific markets will be invaluable as we consolidate and grow our business in the egion. This region is the third largest revenue contributor for us globally and I believe that Fabrice's experience will help Lupin achieve its growth plans for the Asia Pacific region, and help us scale the business to new heights.''
Shares of the company gained Rs 18.15, or 0.88%, to settle at Rs 2,079.45. The total volume of shares traded was 30,163 at the BSE (Friday).